BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, May 15, 2024
See today's BioWorld
Home
» Analysts Bullish on Benlysta as HGSI Reports First Revenue
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Analysts Bullish on Benlysta as HGSI Reports First Revenue
July 25, 2011
By
Trista Morrison
No Comments
Human Genome Sciences Inc. reported net sales of $7.8 million for lupus drug Benlysta (belimumab) in the second quarter, the drug's first full quarter on the market since gaining FDA approval in March. (See BioWorld Today, March 11, 2011.)
BioWorld